Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations

Ioannis Boutsikos; Eleftherios Beltsios; Bastian Schmack; Ioannis Pantazopoulos; Dimitrios G Chatzis

doi:10.17925/HI.2023.17.2.12

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations

Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.

Authors

Ioannis Boutsikos¹, Eleftherios Beltsios², Bastian Schmack², Ioannis Pantazopoulos³, Dimitrios G Chatzis⁴

Affiliations

¹ Department of Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
³ Department of Emergency Medicine, Medical School, University of Thessaly, Larissa, Greece.
⁴ School of Medicine, European University of Cyprus, Nicosia, Cyprus.

Abstract

Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.

Keywords: Diabetic cardiomyopathy; diabetes mellitus; glycosuria; heart insufficiency; renal failure; sodium glucose co-transporter 2 (SGLT2) inhibitors.

Publication types

Review

Grants and funding

Support: No funding was received in the publication of this article.